P806 Development of a clinical model to predict secondary non-response of anti-TNFα treatment on Crohn's disease

Abstract

Abstract Background Secondary non-response to anti-tumor necrosis factor-α (including Infliximab and Adalimumab) in patients with Crohn’s disease (CD) is common. Prediction of secondary non-response is essential for treatment decision for individual patients. Methods The clinical model was constructed in a training cohort. Clinical features, serological parameters, genetic biomarkers etc. were obtained as predictors after anti- TNFα therapy. Univariate analysis was performed to eliminate irrelevant predictors with secondary non-response. A logistic regression model was developed using genetic biomarkers and predictors with P < 0.1 in the univariate analysis. Finally, the model was validated with reference to its calibration and clinical decision curve. Results In a univariate analysis, infliximab antibodies,white blood cell(WBC), albumin(Alb), previous use of immunosuppressant, switching to other drugs, immunological preparation were found associated with secondary non-response to IFX. Logistic regression analysis with stepwise backward selection P < 0.01 and a clinical model was developed based on the above predictors. Conclusion The study presents a model to predict secondary non-response to anti-TNFα in CD. This model can be used to help clinicians adjust the therapeutic strategy for CD patients.